Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 2/3 2Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Docetaxel 7Radiotherapy 6Vincristine 5Etoposide 5Cyclophosphamide 5Cisplatin 5Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Doxorubicin 4Carboplatin 4Capecitabine 4pembrolizumab 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Prednisone 3Oxaliplatin 3Methotrexate 3Leucovorin 3Fluorouracil 3Dexamethasone 3Cytarabine 3Calcium Dobesilate 3Surgical Procedures, Operative 2Ramucirumab 2Radiation 2Pemetrexed 2Mitomycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × NETWORK × Ramucirumab × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Recruiting
378 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡